Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

sections
  • 1 of 1

The high cost of combination treatment lumacaftor/ivacaftor (Orkambi) means it has not been recommended for use in the NHS in England and Wales for cystic fibrosis (CF), draft guidance from the National Institute for Health and Care Excellence (NICE) says

The National Institute for Health and Care Excellence acknowledges how important a new treatment option for cystic fibrosis would be, but says the cost of Orkambi is not justified by the benefits of treatment

Source  National Institute for Health and Care Excellence